Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Capital Leases (2016 - 2018)

Sangamo Therapeutics has reported Capital Leases over the past 3 years, most recently at $27.7 million for Q4 2018.

  • Quarterly results put Capital Leases at $27.7 million for Q4 2018, up 11.93% from a year ago — trailing twelve months through Dec 2018 was $27.7 million (up 11.93% YoY), and the annual figure for FY2018 was $27.7 million, up 11.93%.
  • Capital Leases for Q4 2018 was $27.7 million at Sangamo Therapeutics, up from $26.9 million in the prior quarter.
  • Over the last five years, Capital Leases for SGMO hit a ceiling of $27.7 million in Q4 2018 and a floor of $213000.0 in Q1 2016.
  • Median Capital Leases over the past 3 years was $3.9 million (2016), compared with a mean of $12.4 million.
  • Biggest five-year swings in Capital Leases: surged 1744.13% in 2017 and later increased 11.93% in 2018.
  • Sangamo Therapeutics' Capital Leases stood at $3.9 million in 2016, then soared by 527.07% to $24.7 million in 2017, then rose by 11.93% to $27.7 million in 2018.
  • The last three reported values for Capital Leases were $27.7 million (Q4 2018), $26.9 million (Q3 2018), and $26.2 million (Q2 2018) per Business Quant data.